Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ear zaps may ease Parkinson's speech and movement woes

NCT ID NCT07588191

Symptom relief Sponsor: Universidade da Coruña Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests whether mild electrical stimulation of the ear, combined with physical and speech therapy, can improve symptoms like voice problems, swallowing, and balance in people with Parkinson's disease. 46 participants will receive either active or sham stimulation during 12 sessions over 4 weeks, with follow-up at 8 weeks. The goal is to see if this non-invasive approach can make daily life easier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcutaneous electrical nerve stimulation (TENS) of the vagus nerve in the ear
What this could lead to
If it works, this could offer a non-invasive way to ease speech, swallowing, and movement problems in Parkinson's disease.
What could go wrong
This is a small, early-stage trial with only 46 people. The effects may be modest or not last, and the stimulation might not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Being a member of the Association or be interested in joining; * Idiopathic PD diagnosis, stages 2-3 according to the Hoehn \& Yahr scale; confirmed by neurologist * Ability to walk independently for at least 1 minute ant turn 180° without assistance; * Exhibiting symptoms of hypokinetic dysarthria; * On stable dopaminergic therapy for at least 1 month prior to the experiment Exclusion Criteria: * Any contraindication for taVNS (e.g., ear lesions, pacemakers, defibrillators, or other electronic devices) * Previous vagotomy or previous application of electrical stimulation to the ear or brain, or treatment with high-intensity focused ultrasound (HIFU) * Voice or speech disorders caused by other medical conditions * MoCA score below 21 * Psychotic symptoms or hallucinations; a diagnosis of psychiatric illness * Systolic blood pressure above 160 mm Hg, and diastolic blood pressure above 100 mm Hg * Inability to attend sessions; * Concomitant neurological, orthopaedic, cardiac, respiratory or active medical/oncological condition that would affect participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease (PD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

communication disorder Cough Parkinson disease Sialorrhea Tremor voice disorders Xerostomia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease (PD) Transcutaneous vagal nerve stimulation (TVNS)

Contacts and locations

Locations

  • Association of Parkinson´s Disease Galicia- Coruña

    A Coruña, 15008, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.